Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Oncology Progress》 2018-08
Add to Favorite Get Latest Update

Clinical effect of high dose rate intracavitary brachytherapy in patients with high grade vaginal intraepithelial neoplasia after hysterectomy

LI Fengshuang;WU Yumei;WANG Jiandong;KONG Weimin;SONG Fang;ZHANG Yuxi;YUE Zhiyun;SUN Yang;Department of Gynecological Oncology,Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University;  
Objective To investigate the clinical effect and adverse effect of high dose rate intracavitary brachytherapy(HDR-ICR) in patients with high grade vaginal intraepithelial neoplasia(HG-VAIN) after hysterectomy. Method A retrospective analysis was performed among 13 patients with HG-VAIN. Out of the 13 patients, one case had VAIN II and twelve cases had VAIN III. All patients underwent HDR-ICR as the only treatment, with a vaginal cylinder and/or oval applicator. All patients followed-up and the recurrence, survival status and short and long-term complications were observed. Result The median overall follow-up time for 13 patients was 55 months(range 12-117 months). One case recurred in 22 months after therapy, and were under control after surgery. The totle effective rate of treatment was 92.3%(12/13). Among 13 patients, three patients had short-term complications, including grade 1-2 rectal reaction in 1 case,grade 1 urinary reaction in 2 cases, which were all mild. Six cases had long-term complications, including grade 2 rectal reaction in 3 cases, grade 3 urinary reaction in 2 cases, grade 3-4 vaginal stricture and ulcer in 1 case. Conclusion HDRICR is an effective treatment regimen for patients with HG-VAIN after hysterectomy, with a high cure rate and acceptable short-and long-term complications.
【CateGory Index】: R737.34
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved